idefirix
hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunosuppressantit - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.
orfiril long 150 mg depotkapseli, kova
desitin arzneimittel gmbh - sodium valproate - depotkapseli, kova - 150 mg - valproiinihappo
orfiril long 300 mg depotkapseli, kova
desitin arzneimittel gmbh - sodium valproate - depotkapseli, kova - 300 mg - valproiinihappo
orfiril long 500 mg depotrakeet
desitin arzneimittel gmbh - sodium valproate - depotrakeet - 500 mg - valproiinihappo
orfiril long 1000 mg depotrakeet
desitin arzneimittel gmbh - natrii valproas - depotrakeet - 1000 mg - valproiinihappo
orfiril 100 mg/ml injektioneste, liuos
desitin arzneimittel gmbh - sodium valproate - injektioneste, liuos - 100 mg/ml - valproiinihappo
orfiril 150 mg enterotabletti
rhone-poulenc rorer a/s - natrii valproas - enterotabletti - 150 mg - valproiinihappo
orfiril 300 mg enterotabletti
rhone-poulenc rorer a/s - natrii valproas - enterotabletti - 300 mg - valproiinihappo
orfiril 600 mg enterotabletti
rhone-poulenc rorer a/s - natrii valproas - enterotabletti - 600 mg - valproiinihappo
orfiril 150 mg enterotabletti
desitin arzneimittel gmbh - natrii valproas - enterotabletti - 150 mg - valproiinihappo